Patent Grant
7727763
The invention relates to respiratory epithelial cells, and more particularly, to differentiating multi-lineage progenitor cells (MLPC) from human blood to respiratory epithelial cells, and use of such cells for regenerative therapies.
Progenitor cells capable of hematopoietic reconstitution after mycloablative therapy have been identified in a number of sources including the bone marrow, umbilical cord and placental blood, and in the peripheral blood of subjects treated with stem cell-mobilizing doses of granulocyte-colony stimulation factor. These cells, often referred to as hematopoietic stem cells (HSC), are identified by the presence of cell surface glycoproteins such as CD34 and CD133. HSC represent a very small percentage of the total population of cells given as part of a ‘bone marrow transplant’ and are considered to be the life-saving therapeutic portion of this treatment responsible for the restoration of the blood-forming capacity of patients given myeloablative doses of chemotherapy or radiation therapy. Stem cell therapies via bone marrow transplantation have become a standard treatment for a number of intractable leukemias and genetic blood disorders.
Recent studies have suggested the presence of a more primitive cell population in the bone marrow capable of self-renewal as well as differentiation into a number of different tissue types other than blood cells. These multi-potential cells were discovered as a minor component in the CD34-plastic-adherent cell population of adult bone marrow, and are variously referred to as mesenchymal stem cells (MSC) (Pittenger, et al., Science 284: 143-147 (1999)) or multi-potent adult progenitor cells (MAPC) cells (Furcht, L. T., et al., U.S. patent publication 20040107453 A1). MSC cells do not have a single specific identifying marker, but have been shown to be positive for a number of markers, including CD29, CD90, CD105, and CD73, and negative for other markers, including CD14, CD3, and CD34. Various groups have reported to differentiate MSC cells into myocytes, neurons, pancreatic beta-cells, liver cells, bone cells, and connective tissue. Another group (Wernet et al., U.S. patent publication 20020164794 A1) has described an unrestricted somatic stem cell (USSC) with multi-potential capacity that is derived from a CD45−/CD34− population within cord blood.
The invention is based on the discovery that respiratory epithelial cells can be obtained by inducing differentiation of multi-lineage progenitor cells (MLPC) from human fetal blood. As described herein, fetal blood MLPC are distinguished from bone marrow-derived MSC, HSC, and USSC on the basis of their immunophenotypic characteristics, gene expression profile, morphology, and distinct growth pattern. The invention provides methods for developing monotypic clonal cell lines from individual cells. The invention also provides methods for cryopreserving MLPC (e.g., for cord blood banking) and methods of using MLPC in regenerative therapies.
In one aspect, the invention features a composition that includes a purified population of human fetal blood MLPC or a clonal line of human fetal blood MLPC and a differentiation medium effective to induce differentiation of the MLPC into cells having a respiratory epithelial cell phenotype, wherein the MLPC are positive for CD9, negative for CD45, negative for CD34, and negative for SSEA-4. The differentiation medium can include hydrocortisone, epidermal growth factor, insulin, triiodothyronine, transferrin, and bovine serum albumin. In some embodiments, the differentiation medium further includes retinoic acid, pituitary extract, epinephrine, and/or an antibiotic.
The invention also features a composition that includes a mixture of MLPC and cells having a respiratory epithelial cell phenotype. The composition further can include a culture medium or a differentiation medium. The differentiation medium can include hydrocortisone, epidermal growth factor, insulin, triiodothyronine, transferrin, and bovine serum albumin. In some embodiments, the differentiation medium further includes retinoic acid, pituitary extract, epinephrine, and/or an antibiotic. The culture medium or the differentiation medium can include a cryopreservative.
In another aspect, the invention features a method of producing a population of cells having a respiratory epithelial cell phenotype. The method includes culturing a purified population of MLPC or a clonal line of MLPC with a differentiation medium effective to induce differentiation of the MLPC into cells having the respiratory epithelial cell phenotype, wherein the MLPC are positive for CD9, negative for CD45, negative for CD34, and negative for SSEA-4. The differentiation medium can include hydrocortisone, epidermal growth factor, insulin, triiodothyronine, transferrin, and bovine serum albumin. In some embodiments, the differentiation medium further includes retinoic acid, pituitary extract, epinephrine, and/or an antibiotic. The method further can include testing the cells having the respiratory epithelial cell phenotype for surfactant protein C (e.g., by staining with an antibody having binding affinity for prosurfactant protein C).
In yet another aspect, the invention features a method for producing a population of cells having a respiratory epithelial cell phenotype from human fetal blood. The method includes contacting a human fetal blood sample with a composition, the composition including dextran, anti-glycophorin A antibody, anti-CD15 antibody, and anti-CD9 antibody; allowing the sample to partition into an agglutinate and a supernatant phase; recovering cells from the supernatant phase; purifying MLPC from the recovered cells by adherence to a solid substrate, wherein the MLPC are positive for CD9 and positive for CD45; culturing the MLPC such that the MLPC obtain a fibroblast morphology; and culturing the MLPC having the fibroblast morphology with a differentiation medium effective to induce differentiation of the MLPC into cells having the respiratory epithelial cell phenotype. The method further can include testing the cells having the respiratory epithelial cell phenotype for surfactant protein C. The method also can include producing a clonal line of MLPC from the MLPC having the fibroblast morphology before culturing with the differentiation medium.
The invention also features a clonal population of cells having a respiratory epithelial cell phenotype and compositions containing such clonal populations. Such cells can have enhanced expression of mRNA for a lysosomal ATPase relative to a clonal population of MLPC. In one embodiment, a composition includes a clonal population of cells having a respiratory epithelial cell phenotype and a culture medium. Such compositions further can include a cryopreservative (e.g., dimethylsulfoxide (DMSO) such as 1 to 10% DMSO). The cryopreservative can be fetal bovine serum, human serum, or human serum albumin in combination with one or more of the following: DMSO, trehalose, and dextran. For example, the cryopreservative can be human serum, DMSO, and trehalose, or fetal bovine serum and DMSO.
The invention also features an article of manufacture that includes a clonal population of cells having a respiratory epithelial cell phenotype. The clonal population can be housed within a container (e.g., a vial or a bag). The container further can include a cryopreservative.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
In general, the invention provides purified populations of MLPC from human fetal blood (e.g., umbilical cord blood (“cord blood”), placental blood, or the blood from a fetus) and clonal MLPC lines derived from individual MLPC. Fetal blood provides a source of cells that is more immature than adult bone marrow and has a higher percentage of cells bearing immature cell surface markers. Consequently, there may be advantages in the expansion and differentiation capacity of the progenitor cells from fetal blood. As described herein, MLPC have immunophenotypic characteristics and a gene expression profile distinct from bone marrow derived MSC's, bone marrow-derived HSC, and umbilical cord blood-derived HSC and USSC. The cells described herein have the capacity to self renew and differentiate into diverse cells and tissue types. For example, MLPC are capable of differentiating to respiratory epithelial cells as shown below. MLPC can be used to develop cellular therapies and establish cryopreserved cell banks for future regenerative medicine procedures. MLPC also can be modified such that the cells can produce one or more polypeptides or other therapeutic compounds of interest.
Cell Separation Compositions
MLPC can be isolated from fetal blood (e.g., cord blood) using the negative selection process and cell separation compositions disclosed in U.S. Pat. No. 7,160,723. Such cell compositions can include dextran and one or more antibodies against (i.e., that have binding affinity for) a cell surface antigen.
Dextran is a polysaccharide consisting of glucose units linked predominantly in alpha (1 to 6) mode. Dextran can cause stacking of erythrocytes (i.e., rouleau formation) and thereby facilitate the removal of erythroid cells from solution. Antibodies against cell surface antigens can facilitate the removal of blood cells from solution via homotypic agglutination (i.e., agglutination of cells of the same cell type) and/or heterotypic agglutination (i.e., agglutination of cells of different cell types).
For example, a cell separation composition can include dextran and antibodies against glycophorin A, CD15, and CD9. Cell separation compositions also can contain antibodies against other blood cell surface antigens including, for example, CD2, CD3, CD4, CD8, CD72, CD16, CD41a, HLA Class I, HLA-DR, CD29, CD11a, CD11b, CD11c, CD19, CD20, CD23, CD39, CD40, CD43, CD44, CDw49d, CD53, CD54, CD62L, CD63, CD66, CD67, CD81, CD82, CD99, CD100, Leu-13, TPA-1, surface Ig, and combinations thereof. Thus, cell separation compositions can be formulated to selectively agglutinate particular types of blood cells.
Typically, the concentration of anti-glycophorin A antibodies in a cell separation composition ranges from 0.1 to 15 mg/L (e.g., 0.1 to 10 mg/L, 1 to 5 mg/L, or 1 mg/L). Anti-glycophorin A antibodies can facilitate the removal of red cells from solution by at least two mechanisms. First, anti-glycophorin A antibodies can cause homotypic agglutination of erythrocytes since glycophorin A is the major surface glycoprotein on erythrocytes. In addition, anti-glycophorin A antibodies also can stabilize dextran-mediated rouleau formation. Exemplary monoclonal anti-glycophorin A antibodies include, without limitation, 107FMN (Murine IgG1 isotype), YTH89.1 (Rat IgG2b isotype), 2.2.2.E7 (Murine IgM isotype; BioE, St. Paul, Minn.), and E4 (Murine IgM isotype). See e.g., M. Vanderlaan et al., Molecular Immunology 20:1353 (1983); Telen M. J. and Bolk, T. A., Transfusion 27: 309 (1987); and Outram S. et al., Leukocyte Research. 12:651 (1988).
The concentration of anti-CD 15 antibodies in a cell separation composition can range from 0.1 to 15 mg/L (e.g., 0.1 to 10, 1 to 5, or 1 mg/L). Anti-CD15 antibodies can cause homotypic agglutination of granulocytes by crosslinking CD 15 molecules that are present on the surface of granulocytes. Anti CD15 antibodies also can cause homotypic and heterotypic agglutination of granulocytes with monocytes, NK-cells and B-cells by stimulating expression of adhesion molecules (e.g., L-selectin and beta-2 integrin) on the surface of granulocytes that interact with adhesion molecules on monocytes, NK-cells and B-cells. Heterotypic agglutination of these cell types can facilitate the removal of these cells from solution along with red cell components. Exemplary monoclonal anti-CD15 antibodies include, without limitation, AHN1.1 (Murine IgM isotype), FMC-10 (Murine IgM isotype), BU-28 (Murine IgM isotype), MEM-157 (Murine IgM isotype), MEM-158 (Murine IgM isotype), 324.3.B9 (Murine IgM isotype; BioE, St. Paul, Minn.), and MEM-167 (Murine IgM isotype). See e.g., Leukocyte typing IV (1989); Leukocyte typing II (1984); Leukocyte typing VI (1995); Solter D. et al., Proc. Natl. Acad. Sci. USA 75:5565 (1978); Kannagi R. et al., J. Biol. Chem. 257:14865 (1982); Magnani, J. L. et al., Arch. Biochem. Biophys 233:501 (1984); Eggens I. et al., J. Biol. Chem. 264:9476 (1989).
The concentration of anti-CD9 antibodies in a cell separation composition can range from 0.1 to 15, 0.1 to 10, 1 to 5, or 1 mg/L. Anti-CD9 antibodies can cause homotypic agglutination of platelets. Anti-CD9 antibodies also can cause heterotypic agglutination of granulocytes and monocytes via platelets that have adhered to the surface of granulocytes and monocytes. CD9 antibodies can promote the expression of platelet p-selectin (CD62P), CD41/61, CD31, and CD36, which facilitates the binding of platelets to leukocyte cell surfaces. Thus, anti-CD9 antibodies can promote multiple cell-cell linkages and thereby facilitate agglutination and removal from solution. Exemplary monoclonal anti-CD9 antibodies include, without limitation, MEM-61 (Murine IgG1 isotype), MEM-62 (Murine IgG1 isotype), MEM-192 (Murine IgM isotype), FMC-8 (Murine IgG2a isotype), SN4 (Murine IgG1 isotype), 8.10.E7 (Murine IgM isotype; BioE, St. Paul, Minn.), and BU-16 (Murine IgG2a isotype). See e.g., Leukocyte typing VI (1995); Leukocyte typing II (1984); Von dem Bourne A. E. G. Kr. and Moderman P. N. (1989) In Leukocyte typing IV (ed. W. Knapp, et al), pp. 989-92, Oxford University Press, Oxford; Jennings, L. K., et al. In Leukocyte typing V, ed. S. F. Schlossmann et al., pp. 1249-51, Oxford University Press, Oxford (1995); Lanza F. et al., J. Biol. Chem. 266:10638 (1991); Wright et al., Immunology Today 15:588 (1994); Rubinstein E. et al., Seminars in Thrombosis and Hemostasis 21:10 (1995).
In some embodiments, a cell separation composition contains antibodies against CD41, which can selectively agglutinate platelets. In some embodiments, a cell separation composition contains antibodies against CD3, which can selectively agglutinate T-cells. In some embodiments, a cell separation composition contains antibodies against CD2, which can selectively agglutinate T-cells and NK cells. In some embodiments, a cell separation composition contains antibodies against CD72, which can selectively agglutinate B-cells. In some embodiments, a cell separation composition contains antibodies against CD16, which can selectively agglutinate NK cells and neutrophilic granulocytes. The concentration of each of these antibodies can range from 0.01 to 15 mg/L. Exemplary anti-CD41 antibodies include, without limitation, PLT-1 (Murine IgM isotype), CN19 (Murine IgG1 isotype), and 8.7.C3 (Murine IgG1 isotype). Non-limiting examples of anti-CD3 antibodies include OKT3 (Murine IgG1), HIT3a (Murine IgG2a isotype), SK7 (Murine IgG1) and BC3 (Murine IgG2a). Non-limiting examples of anti-CD2 antibodies include 7A9 (Murine IgM isotype), T11 (Murine IgG1 isotype), and Leu5b (Murine IgG2a Isotype). Non-limiting examples of anti-CD72 antibodies include BU-40 (Murine IgG1 isotype) and BU-41 (Murine IgG1 isotype). Non-limiting examples of anti-CD16 antibodies include 3G8 (Murine IgG).
As mentioned above, cell separation compositions can be formulated to selectively agglutinate particular blood cells. As an example, a cell separation composition containing antibodies against glycophorin A, CD15, and CD9 can facilitate the agglutination of erythrocytes, granulocytes, NK cells, B cells, and platelets. T cells, NK cells and rare precursor cells such as MLPC then can be recovered from solution. If the formulation also contained an antibody against CD3, T cells also could be agglutinated, and NK cells and rare precursors such as MLPC could be recovered from solution.
Cell separation compositions can contain antibodies against surface antigens of other types of cells (e.g., cell surface proteins of tumor cells). Those of skill in the art can use routine methods to prepare antibodies against cell surface antigens of blood, and other, cells from humans and other mammals, including, for example, non-human primates, rodents (e.g., mice, rats, hamsters, rabbits and guinea pigs), swine, bovines, and equines.
Typically, antibodies used in the composition are monoclonal antibodies, which are homogeneous populations of antibodies to a particular epitope contained within an antigen. Suitable monoclonal antibodies are commercially available, or can be prepared using standard hybridoma technology. In particular, monoclonal antibodies can be obtained by techniques that provide for the production of antibody molecules by continuous cell lines in culture, including the technique described by Kohler, G. et al., Nature, 1975, 256:495, the human B-cell hybridoma technique (Kosbor et al., Immunology Today 4:72 (1983); Cole et al., Proc. Natl. Acad. Sci. USA 80:2026 (1983)), and the EBV-hybridoma technique (Cole et al., “Monoclonal Antibodies and Cancer Therapy,” Alan R. Liss, Inc., pp. 77-96 (1983)).
Antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD, and any subclass thereof Antibodies of the IgG and IgM isotypes are particularly useful in cell separation compositions of the invention. Pentameric IgM antibodies contain more antigen binding sites than IgG antibodies and can, in some cases (e.g., anti-glycophorin A and anti-CD 15), be particularly useful for cell separation reagents. In other cases (e.g., anti-CD9 antibodies), antibodies of the IgG isotype are particularly useful for stimulating homotypic and/or heterotypic agglutination.
Antibodies against cell surface antigens can be provided in liquid phase (i.e., soluble). Liquid phase antibodies typically are provided in a cell separation composition at a concentration between about 0.1 and about 15 mg/l (e.g., between 0.25 to 10, 0.25 to 1, 0.5 to 2, 1 to 2, 4 to 8, 5 to 10 mg/l).
Antibodies against cell surface antigens also can be provided in association with a solid phase (i.e., substrate-bound). Antibodies against different cell surface antigens can be covalently linked to a solid phase to promote crosslinking of cell surface molecules and activation of cell surface adhesion molecules. The use of substrate-bound antibodies can facilitate cell separation (e.g., by virtue of the mass that the particles contribute to agglutinated cells, or by virtue of properties useful for purification).
In some embodiments, the solid phase with which a substrate-bound antibody is associated is particulate. In some embodiments, an antibody is bound to a latex microparticle such as a paramagnetic bead (e.g., via biotin-avidin linkage, covalent linkage to COO groups on polystyrene beads, or covalent linkage to NH2 groups on modified beads). In some embodiments, an antibody is bound to an acid-etched glass particle (e.g., via biotin-avidin linkage). In some embodiments, an antibody is bound to an aggregated polypeptide such as aggregated bovine serum albumin (e.g., via biotin-avidin linkage, or covalent linkage to polypeptide COO groups or NH2 groups). In some embodiments, an antibody is covalently linked to a polysaccharide such as high molecular weight (e.g., >1,000,000 Mr) dextran sulfate. In some embodiments, biotinylated antibodies are linked to avidin particles, creating tetrameric complexes having four antibody molecules per avidin molecule. In some embodiments, antibodies are bound to biotinylated agarose gel particles (One Cell Systems, Cambridge, Mass., U.S.A.) via biotin-avidin-biotinylated antibody linkages. Such particles typically are about 300-500 microns in size, and can be created in a sonicating water bath or in a rapidly mixed water bath.
Cell-substrate particles (i.e., particles including cells and substrate-bound antibodies) can sediment from solution as an agglutinate. Cell-substrate particles also can be removed from solution by, for example, an applied magnetic field, as when the particle is a paramagnetic bead. Substrate-bound antibodies typically are provided in a cell separation composition at a concentration between about 0.1 and about 50.0×109 particles/1 (e.g., between 0.25 to 10.0×109, 1 to 20.0×109, 2 to 10.0×109, 0.5 to 2×109, 2 to 5×109, 5 to 10×109, and 10 to 30×109 particles/1), where particles refers to solid phase particles having antibodies bound thereto.
Cell separation compositions also can contain divalent cations (e.g., Ca+2 and Mg+2). Divalent cations can be provided, for example, by a balanced salt solution (e.g., Hank's balanced salt solution). Ca+2 ions reportedly are important for selectin-mediated and integrin-mediated cell-cell adherence.
Cell separation compositions also can contain an anticoagulant such as heparin. Heparin can prevent clotting and non-specific cell loss associated with clotting in a high calcium environment. Heparin also promotes platelet clumping. Clumped platelets can adhere to granulocytes and monocytes and thereby enhance heterotypic agglutination more so than single platelets. Heparin can be supplied as a heparin salt (e.g., sodium heparin, lithium heparin, or potassium heparin).
Populations and Clonal Lines of MLPC
MLPC can be purified from human fetal blood using a cell separation composition described above. As used herein, “purified” means that at least 90% (e.g., 91, 92, 93, 94, 95, 96, 97, 98, or 99%) of the cells within the population are MLPC. As used herein, “MLPC” refers to fetal blood cells that are positive for CD9 and typically display a constellation of other markers such as CD13, CD73, and CD105. “MLPC population” refers to the primary culture obtained from the human fetal blood and uncloned progeny thereof. “Clonal line” refers to a cell line derived from a single cell. As used herein, a “cell line” is a population of cells able to renew themselves for extended periods of times in vitro under appropriate culture conditions. The term “line,” however, does not indicate that the cells can be propagated indefinitely. Rather, clonal lines described herein typically can undergo 75 to 100 doublings before senescing.
Typically, an MLPC population is obtained by contacting a fetal blood sample with a cell separation composition described above and allowing the sample to partition into an agglutinate and a supernatant phase. For example, the sample can be allowed to settle by gravity or by centrifugation. Preferably, MLPC are purified from an umbilical cord blood sample that is less than 48 hours old (e.g., less than 24, 12, 8, or 4 hours post-partum). After agglutination, unagglutinated cells can be recovered from the supernatant phase. For example, cells in the supernatant phase can be recovered by centrifugation then washed with a saline solution and plated on a solid substrate (e.g., a plastic culture device such as a chambered slide or culture flask), using a standard growth medium with 10% serum (e.g., DMEM with 10% serum; RPMI-1640 with 10% serum, or mesenchymal stem cell growth medium with 10% serum (catalog #PT-3001, Cambrex, Walkersville, Md.). MLPC attach to the surface of the solid substrate while other cells, including T cells, NK cells and CD34+ HSC, do not and can be removed with washing. The MLPC change from the leukocyte morphology to the fibroblastic morphology between 3 days and 2 weeks post initiation of culture after which the cells enter logarithmic growth phase and will continue growing logarithmically as long as cultures are maintained at cell concentrations of less than about 1.5×105 cells/cm2. In some of the example herein, this is referred to as a “mixed cell line.”
Clonal lines can be established by harvesting the MLPC then diluting and re-plating the cells on a multi-well culture plate such that a single cell can be found in a well. Cells can be transferred to a larger culture flask after a concentration of 1 to 5×105 cells/75 cm2 is reached. Cells can be maintained at a concentration between 1×105 and 5×105 cells/75 cm2 for logarithmic growth. See, e.g., U.S. Patent Publication No. 2005-0255592-A.
MLPC can be assessed for viability, proliferation potential, and longevity using techniques known in the art. For example, viability can be assessed using trypan blue exclusion assays, fluorescein diacetate uptake assays, or propidium iodide uptake assays. Proliferation can be assessed using thymidine uptake assays or MTT cell proliferation assays. Longevity can be assessed by determining the maximum number of population doublings of an extended culture.
MLPC can be immunophenotypically characterized using known techniques. For example, the cell culture medium can be removed from the tissue culture device and the adherent cells washed with a balanced salt solution (e.g., Hank's balanced salt solution) and bovine serum albumin (e.g., 2% BSA). Cells can be incubated with an antibody having binding affinity for a cell surface antigen such as CD9, CD45, CD13, C73, CD105, or any other cell surface antigen. The antibody can be detectably labeled (e.g., fluorescently or enzymatically) or can be detected using a secondary antibody that is detectably labeled. Alternatively, the cell surface antigens on MLPC can be characterized using flow cytometry and fluorescently labeled antibodies.
As described herein, the cell surface antigens present on MLPC can vary, depending on the stage of culture. Early in culture when MLPC display a leukocyte-like morphology, MLPC are positive for CD9 and CD45, SSEA-4 (stage-specific embryonic antigen-4), CD34, as well as CD13, CD29, CD44, CD73, CD90, CD105, stem cell factor, STRO-1 (a cell surface antigen expressed by bone marrow stromal cells), SSEA-3 (galactosylgloboside), and CD133, and are negative for CD15, CD38, glycophorin A (CD235a), and lineage markers CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD16, CD19, CD20, CD21, CD22, CD33, CD36, CD41, CD61, CD62E, CD72, HLA-DR, and CD102. After transition to the fibroblastic morphology, MLPC remain positive for CD9, CD13, CD29, CD73, CD90, and CD105, and become negative for CD34, CD41, CD45, stem cell factor, STRO-1, SSEA-3, SSEA-4, and CD133. At all times during in vitro culture, the undifferentiated MLPC are negative for CD15, CD38, glycophorin A (CD235a), and lineage markers CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD16, CD19, CD20, CD21, CD22, CD33, CD36, CD41, CD61, CD62E, CD72, HLA-DR, and CD102.
Bone marrow-derived MSC and MAPC as well as the cord blood-derived USSC have been described as being derived from a CD45−/CD34− cell population. MLPC are distinguished from those cell types as being a CD45+/CD34+ derived cell. Additionally, the presence and persistence of CD9 on the fetal blood-derived MLPC at all stages of maturation further distinguishes MLPC from MSC and MAPC, which do not possess CD9 as a marker. CD9 is expressed as a marker on human embryonic stem cells. MLPC, which share the hematopoietic markers CD45, CD133, CD90 and CD34 during their leukocyte morphology phase, can be distinguished from HSC by their obligate plastic adherence and the presence of mesenchymal associated markers CD105, CD29, CD73, CD13 and embryonic associated markers SSEA-3 and SSEA-4. Additionally using currently available technology, HSC are unable to be cultured in vitro without further differentiation while MLPC can be expanded for many generations without differentiation. MLPC also differ from MSC and USSC by their more gracile in vitro culture appearance, thread-like cytoplasmic projections and their preference for low density culture conditions for optimal growth.
MLPC also can be characterized based on the expression of one or more genes. Methods for detecting gene expression can include, for example, measuring levels of the mRNA or protein of interest (e.g., by Northern blotting, reverse-transcriptase (RT)-PCR, microarray analysis, Western blotting, ELISA, or immunohistochemical staining). The gene expression profile of MLPC is significantly different than other cell types. Microarray analysis indicated that the MLPC lines have an immature phenotype that differs from the phenotypes of, for example, CD133+HSC, lineage negative cells (Forrz et al., Stem Cells, 22(1):100-108 (2004)), and MSC (catalog #PT-2501, Cambrex, Walkersville, Md., U.S. Pat. No. 5,486,359), which demonstrate a significant degree of commitment down several lineage pathways.
Comparison of the gene expression profile of MLPC and MSC demonstrates MSC are more committed to connective tissue pathways. There are 80 genes up-regulated in MSC, and 152 genes up-regulated in MLPC. In particular, the following genes were up-regulated in MLPC when compared with MSC, i.e., expression was decreased in MSC relative to MLPC: ITGB2, ARHGAP9, CXCR4, INTEGRINB7, PECAM1, PRKCB—1, PRKCB—3, IL7R, AIF1, CD45_EX10-11, PLCG2, CD37, PRKCB—2, TCF2—1, RNF138, EAAT4, EPHA1, RPLP0, PTTG, SERPINA1—2, ITGAX, CD24, F11RPL4, ICAM1, LMO2, HMGB2, CD38, RPL7A, BMP3, PTHR2, S100B, OSF, SNCA, GRIK1, HTR4, CHRM1, CDKN2D, HNRPA1, IL6R, MUSLAMR, ICAM2, CSK, ITGA6, MMP9, DNMT1, PAK1, IKKB, TFRC_MIDDLE, CHI3L2, ITGA4, FGF20, NBR2, TNFRSF1B, CEBPA—3, CDO1, NFKB1, GATA2, PDGFRB, ICSBP1, KCNE3, TNNC1, ITGA2B, CCT8, LEFTA, TH, RPS24, HTR1F, TREM1, CCNB2, SELL, CD34, HMGIY, COX7A2, SELE, TNNT2, SEM2, CHEK1, CLCN5, F5, PRKCQ, ITGAL, NCAM2, ZNF257-MGC12518-ZNF92-ZNF43-ZNF273-FLJ90430, CDK1, RPL6, RPL24, IGHA1-IGHA2_M, PUM2, GJA7, HTR7, PTHR1, MAPK14, MSI2—1, KCNJ3, CD133, SYP, TFRC—5PRIME, TDGF1-TDGF3—2, FLT3, HPRT, SEMA4D, ITGAM, KIAA0152—3, ZFP42, SOX20, FLJ21190, CPN2, POU2F2, CASP8—1, CLDN10, TREM2, TERT, OLIG1, EGR2, CD44_EX3-5, CD33, CNTFR, OPN, COL9A1—2, ROBO4, HTR1D—1, IKKA, KIT, NPPA, PRKCH, FGF4, CD68, NUMB, NRG3, SALL2, NOP5, HNF4G, FIBROMODULIN, CD58, CALB1, GJB5, GJA5, POU5F—1, GDF5, POU6F1, CD44_EX16-20, BCAN, PTEN1-PTEN2, AGRIN, ALB, KCNQ4, DPPA5, EPHB2, TGFBR2, and ITGA3. See, e.g., U.S. Patent Publication No. 2006-0040392-A1.
MLPC express a number of genes associated with “stemness,” which refers to the ability to self-renew undifferentiated and ability to differentiate into a number of different cell types. Genes associated with “stemness” include the genes known to be over-expressed in human embryonic stem cells, including, for example, POU5F (October 4), TERT, and ZFP42. For example, 65 genes associated with protein synthesis are down-regulated, 18 genes linked with phosphate metabolism are down-regulated, 123 genes regulating proliferation and cell cycling are down-regulated, 12 different gene clusters associated with differentiation surface markers are down-regulated, e.g., genes associated with connective tissue, including integrin alpha-F, laminin and collagen receptor, ASPIC, thrombospondins, endothelium endothelin-1 and -2 precursors, epidermal CRABP-2, and genes associated with adipocytes, including, for example, the leptin receptor, and 80 genes linked to nucleic acid binding and regulation of differentiation are up-regulated. Thus, the immaturity of a population of MLPC can be characterized based on the expression of one or more genes (e.g., one or more of CXCR4, FLT3, TERT, KIT, POU5F, or hematopoietic CD markers such as CD9, CD34, and CD133). See, e.g., U.S. Patent Publication No. 2006-0040392-A1.
MLPC can be cryopreserved by suspending the cells (e.g. 5×106 to 2×107 cells/mL) in a cryopreservative such as dimethylsulfoxide (DMSO, typically 1 to 10%) or in fetal bovine serum, human serum, or human serum albumin in combination with one or more of DMSO, trehalose, and dextran. For example, (1) fetal bovine serum containing 10% DMSO; (2) human serum containing 10% DMSO and 1% Dextran; (3) human serum containing 1% DMSO and 5% trehalose; or (4) 20% human serum albumin, 1% DMSO, and 5% trehalose can be used to cryopreserve MLPC. After adding cryopreservative, the cells can be frozen (e.g., to −90° C.). In some embodiments, the cells are frozen at a controlled rate (e.g., controlled electronically or by suspending the cells in a bath of 70% ethanol and placed in the vapor phase of a liquid nitrogen storage tank. When the cells are chilled to −90° C., they can be placed in the liquid phase of the liquid nitrogen storage tank for long term storage. Cryopreservation can allow for long-term storage of these cells for therapeutic use.
Differentiation of MLPC
MLPC are capable of differentiating into a variety of cells, including cells of each of the three embryonic germ layers (i.e., endoderm, ectoderm, and mesoderm). As used herein, “capable of differentiating” means that a given cell, or its progeny, can proceed to a differentiated phenotype under the appropriate culture conditions. For example, MLPC can differentiate into cells having an osteocytic phenotype, cells having an adipocytic phenotype, cells having a neurocytic phenotype, cells having a myocytic phenotype, cells having an endothelial phenotype, cells having a hepatocytic/pancreatic precursor phenotype (also known as an oval cell), cells having a respiratory epithelial cell phenotype, as well as other cell types. A clonal population of differentiated cells (e.g., cells having a respiratory epithelial cell phenotype) is obtained when a clonal line of MLPC is differentiated.
Differentiation can be induced using one or more differentiation agents, including without limitation, Ca2+, an epidermal growth factor (EGF), a platelet derived growth factor (PDGF), a keratinocyte growth factor (KGF), a transforming growth factor (TGF), cytokines such as an interleukin, an interferon, or tumor necrosis factor, retinoic acid, transferrin, hormones (e.g., androgen, estrogen, insulin, prolactin, triiodothyronine, hydrocortisone, or dexamethasone), sodium butyrate, TPA, DMSO, NMF (N-methyl formamide), DMF (dimethylformamide), or matrix elements such as collagen, laminin, heparan sulfate).
Determination that an MLPC has differentiated into a particular cell type can be assessed using known methods, including, measuring changes in morphology and cell surface markers (e.g., by flow cytometry or immunohistochemistry), examining morphology by light or confocal microscopy, or by measuring changes in gene expression using techniques such as polymerase chain reaction (PCR) or gene-expression profiling.
For example, MLPC can be induced to differentiate into cells having an osteocytic phenotype using an induction medium (e.g., Osteogenic Differentiation Medium, catalog #PT-3002, from Cambrex) containing dexamethasone, L-glutamine, ascorbate, and β-glycerophosphate (Jaiswal et al., J. Biol. Chem. 64(2):295-312 (1997)). Cells having an osteocytic phenotype contain deposits of calcium crystals, which can be visualized, for example, using Alizarin red stain.
MLPC can be induced to differentiate into cells having an adipocytic phenotype using an induction medium (e.g., Adipogenic Differentiation Medium, catalog #PT-3004, from Cambrex) containing insulin, L-glutamine, dexamethasone, indomethacin, and 3-isobutyl-1-methyl-xanthine. Cells having an adipocytic phenotype contain lipid filled liposomes that can be visualized with Oil Red stain. Such cells also contain trigycerides, which fluoresce green with Nile Red stain (Fowler and Greenspan, Histochem. Cytochem. 33:833-836 (1985)).
MLPC can be induced to differentiate into cells having a myocytic phenotype using an induction medium (e.g., SkGM™, catalog #CC-3160, from Cambrex) containing EGF, insulin, Fetuin, dexamethasone, and FGF-basic (Wernet, et al., U.S. patent publication 20020164794 A1). Cells having a myocytic phenotype express fast skeletal muscle myosin and alpha actinin.
MLPC can be induced to differentiate into cells having a neural stem cell phenotype (neurospheres) using an induction medium (e.g., NPMM™—Neural Progenitor Maintenance medium, catalog #CC-3209, from Cambrex) containing human FGF-basic, human EGF, NSF-1, and FGF-4 and a culture device pre-coated with poly-D-lysine and laminin (e.g., from BD Biosciences Discovery Labware, catalog #354688). Once cells have been differentiated into neurospheres, they can be further differentiated into motor neurons with the addition of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), astrocytes with the addition of leukemia inhibitory factor (LIF), retinoic acid and ciliary neurotrophic factor, and oligodendrocytes with the addition of 3,3′,5-triiodo-L-thyronine (T3). Neurocytic differentiation can be confirmed by the expression of nestin, class III beta-tubulin (tubulin β-4), glial fibrillary acidic protein (GFAP), and galactocerebroside (GalC). Neurospheres are positive for all such markers while some differentiated cell types are not. Differentiation into oligodendrocytes can be confirmed by positive staining for myelin basic protein (MBP).
MLPC can be induced to differentiate into cells having an endothelial phenotype using an endothelial growth medium (e.g., EGM™-MV, catalog #CC-3125, from Cambrex) containing heparin, bovine brain extract, epithelial growth factor (e.g., human recombinant epithelial growth factor), and hydrocortisone. Endothelial differentiation can be confirmed by expression of E-selectin (CD62E), ICAM-2 (CD102), CD34, and STRO-1.
MLPC can be induced to differentiate into cells having a hepatocyte/pancreatic precursor cell phenotype using an induction medium (e.g., HCM™—hepatocyte culture medium, catalog #CC-3198, from Cambrex) containing ascorbic acid, hydrocortisone, transferrin, insulin, EGF, hepatocyte growth factor, FGF-basic, fibroblast growth factor-4, and stem cell factor. Liver and pancreas cells share a common progenitor. Hepatocyte differentiation can be confirmed by expression of hepatocyte growth factor and human serum albumin. Pancreatic cell differentiation can be confirmed by production of insulin and pro-insulin.
MLPC can be induced to differentiate into cells having a respiratory epithelium phenotype. For example, MLPC can be induced to differentiate into type II alveolar cells, which also are known as type II pneumocytes. A medium can be used that contains one or more of pituitary extract (e.g. a bovine pituitary extract), steroid hormones (e.g. hydrocortisone, or a salt thereof such as the acetate), growth factors (e.g., epidermal growth factor, preferably human epidermal growth factor), catecholamines (e.g., epinephrine, either in racemic or enantiomeric form), iron-binding proteins (e.g., a transferrin), insulin, vitamins (e.g., retinoic acid), thyroid hormones (e.g., triiodothyronine), serum albumins (e.g., bovine or human serum albumin, including recombinant preparations), antibiotics (e.g., aminoglycoside antibiotics, such as gentamicin), and/or antifingals (e.g. amphotericin-B). For example, a medium can include hydrocortisone, epidermal growth factor, insulin, triiodothyronine, transferrin, and bovine serum albumin and in some embodiments, further can include retinoic acid, pituitary extract, and epinephrine. SAGM™ medium from Cambrex (catalog CC-3118) is particularly useful for differentiating MLPC into type II alveolar cells. Differentiation to respiratory epithelial cells (e.g., type II alveolar cells) can be confirmed, for example, by an epithelioid morphology as assessed by light microscopy and the presence of lamellar bodies and microvesicular bodies as assessed by transmission electron microscopy. Lamellar bodies are secretory lysosomes that serve as the storage form of lung surfactant, surfactant protein C (SPC), which is an integral membrane protein that is expressed only in type II alveolar cells. The presence of SPC mRNA can be detected by reverse-transcriptase PCR and the presence of SPC protein can be detected by immunofluorescence staining. Clonal populations of respiratory epithelial cells (i.e., a plurality of respiratory epithelial cells obtained from a clonal line of MLPC) are particularly useful, for example, in terminal airway models, chronic airway disease (e.g., COPD), lung injury (including injury induced by therapeutic means such as adiation for various diseases/illnesses), surfactant deficiency, alpha-1 anti-trypsin deficiency, and cystic fibrosis.
Modified Populations of MLPC
MLPC can be modified such that the cells can produce one or more polypeptides or other therapeutic compounds of interest. To modify the isolated cells such that a polypeptide or other therapeutic compound of interest is produced, the appropriate exogenous nucleic acid must be delivered to the cells. In some embodiments, the cells are transiently transfected, which indicates that the exogenous nucleic acid is episomal (i.e., not integrated into the chromosomal DNA). In other embodiments, the cells are stably transfected, i.e., the exogenous nucleic acid is integrated into the host cell's chromosomal DNA. The term “exogenous” as used herein with reference to a nucleic acid and a particular cell refers to any nucleic acid that does not originate from that particular cell as found in nature. In addition, the term “exogenous” includes a naturally occurring nucleic acid. For example, a nucleic acid encoding a polypeptide that is isolated from a human cell is an exogenous nucleic acid with respect to a second human cell once that nucleic acid is introduced into the second human cell. The exogenous nucleic acid that is delivered typically is part of a vector in which a regulatory element such as a promoter is operably linked to the nucleic acid of interest.
Cells can be engineered using a viral vector such as an adenovirus, adeno-associated virus (AAV), retrovirus, lentivirus, vaccinia virus, measles viruses, herpes viruses, or bovine papilloma virus vector. See, Kay et al. (1997) Proc. Natl. Acad. Sci. USA 94:12744-12746 for a review of viral and non-viral vectors. A vector also can be introduced using mechanical means such as liposomal or chemical mediated uptake of the DNA. For example, a vector can be introduced into an MLPC by methods known in the art, including, for example, transfection, transformation, transduction, electroporation, infection, microinjection, cell fusion, DEAE dextran, calcium phosphate precipitation, liposomes, LIPOFECTIN™, lysosome fusion, synthetic cationic lipids, use of a gene gun or a DNA vector transporter.
A vector can include a nucleic acid that encodes a selectable marker. Non-limiting examples of selectable markers include puromycin, adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo, G418, APH), dihydrofolate reductase (DHFR), hygromycin-B-phosphtransferase, thymidine kinase (TK), and xanthin-guanine phosphoribosyltransferase (XGPRT). Such markers are useful for selecting stable transformants in culture.
MLPC also can have a targeted gene modification. Homologous recombination methods for introducing targeted gene modifications are known in the art. To create a homologous recombinant MLPC, a homologous recombination vector can be prepared in which a gene of interest is flanked at its 5′ and 3′ ends by gene sequences that are endogenous to the genome of the targeted cell, to allow for homologous recombination to occur between the gene of interest carried by the vector and the endogenous gene in the genome of the targeted cell. The additional flanking nucleic acid sequences are of sufficient length for successful homologous recombination with the endogenous gene in the genome of the targeted cell. Typically, several kilobases of flanking DNA (both at the 5′ and 3′ ends) are included in the vector. Methods for constructing homologous recombination vectors and homologous recombinant animals from recombinant stem cells are commonly known in the art (see, e.g., Thomas and Capecehi, 1987, Cell 51:503; Bradley, 1991, Curr. Opin. Bio/Technol. 2:823-29; and PCT Publication Nos. WO 90/11354, WO 91/01140, and WO 93/04169.
Methods of Using MLPC
The MLPC can be used in enzyme replacement therapy to treat specific diseases or conditions, including, but not limited to lysosomal storage diseases, such as Tay-Sachs, Niemann-Pick, Fabry's, Gaucher's, Hunter's, and Hurler's syndromes, as well as other gangliosidoses, mucopolysaccharidoses, and glycogenoses.
In other embodiments, the cells can be used as carriers in gene therapy to correct inborn errors of metabolism, adrenoleukodystrophy, cystic fibrosis, glycogen storage disease, hypothyroidism, sickle cell anemia, Pearson syndrome, Pompe's disease, phenylketonuria (PKIJ), porphyrias, maple syrup urine disease, homocystinuria, mucoplysaccharide nosis, chronic granulomatous disease and tyrosinemia and Tay-Sachs disease or to treat cancer, tumors or other pathological conditions.
MLPC can be used to repair damage of tissues and organs resulting from disease. In such an embodiment, a patient can be administered a population of MLPC to regenerate or restore tissues or organs which have been damaged as a consequence of disease. For example, a population of MLPC can be administered to a patient to enhance the immune system following chemotherapy or radiation, to repair heart tissue following myocardial infarction, or to repair lung tissue after lung injury or disease.
The cells also can be used in tissue regeneration or replacement therapies or protocols, including, but not limited to treatment of corneal epithelial defects, cartilage repair, facial dermabrasion, mucosal membranes, tympanic membranes, intestinal linings, neurological structures (e.g., retina, auditory neurons in basilar membrane, olfactory neurons in olfactory epithelium), burn and wound repair for traumatic injuries of the skin, or for reconstruction of other damaged or diseased organs or tissues.
MLPC also can be used in therapeutic transplantation protocols, e.g., to augment or replace stem or progenitor cells of the liver, pancreas, kidney, lung, nervous system, muscular system, bone, bone marrow, thymus, spleen, mucosal tissue, gonads, or hair.
Compositions and Articles of Manufacture
The invention also features compositions and articles of manufacture containing purified populations of MLPC or clonal lines of MLPC. In some embodiments, the purified population of MLPC or clonal line is housed within a container (e.g., a vial or bag). In some embodiments, the clonal lines have undergone at least 3 doublings in culture (e.g., at least 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 doublings). In other embodiments, a culture medium (e.g., MSCGM™ medium or SAGM™) is included in the composition or article of manufacture. In some embodiments, the composition includes a mixed population of cells. For example, the composition can include MLPC and cells having a respiratory epithelial cell phenotype. In still other embodiments, the composition or article of manufacture can include one or more cryopreservatives or pharmaceutically acceptable carriers. For example, a composition can include serum and DMSO, a mixture of serum, DMSO, and trehalose, or a mixture of human serum albumin, DMSO, and trehalose.
Purified populations of MLPC or clonal MLPC lines can be combined with packaging material and sold as a kit. For example, a kit can include purified populations of MLPC or clone MLPC lines and a differentiation medium effective to induce differentiation of the MLPC into cells having a respiratory epithelial cell phenotype. The differentiation medium can include hydrocortisone, epidermal growth factor, insulin, triiodothyronine, transferrin, and bovine serum albumin, and in some embodiments, further include retinoic acid, pituitary extract, epinephrine, and/or an antibiotic. The packaging material included in a kit typically contains instructions or a label describing how the purified populations of MLPC or clonal lines can be grown, differentiated, or used. A label also can indicate that the MLPC have enhanced expression of, for example, CXCR4, FLT3, or CD133 relative to a population of MSC. Components and methods for producing such kits are well known.
In other embodiments, an article of manufacture or kit can include differentiated progeny of MLPC or differentiated progeny of clonal MLPC lines. For example, an article of manufacture or kit can include a clonal population of cells having a respiratory epithelial phenotype (e.g., type II alveolar cells) and a culture medium, and further can include one or more cryopreservatives. In some embodiments, the clonal population of cells is housed within a container such as a vial or bag.
An article of manufacture or kit also can include one or more reagents for characterizing a population of MLPC, a clonal MLPC line, or differentiated progeny of MLPC. For example, a reagent can be a nucleic acid probe or primer for detecting expression of a gene such as CXCR4, FLT3, CD133, CD34, TERT, KIT, POU5F, ICAM2, ITGAX, TFRC, KIT, IL6R, IL7R, ITGAM, FLT3, PDGFRB, SELE, SELL, TFRC, ITGAL, ITGB2, PECAM1, ITGA2B, ITGA3, ITGA4, ITGA6, ICAM1, CD24, CD44, CD45, CD58, CD68, CD33, CD37, or CD38. Such a nucleic acid probe or primer can be labeled, (e.g., fluorescently or with a radioisotope) to facilitate detection. A reagent also can be an antibody having specific binding affinity for a cell surface marker such as CD9, CD45, SSEA-4, CD34, CD13, CD29, CD41, CD44, CD73, CD90, CD105, stem cell factor, STRO-1, SSEA-3, CD133, CD15, CD38, glycophorin A (CD235a), CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD13, CD16, CD19, CD20, CD21, CD22, CD29, CD33, CD36, CD41, CD61, CD62E, CD72, CD73, CD90, HLA-DR, CD102, CD105, or a membrane protein such as prosurfactant protein C or surfactant protein C. An antibody can be detectably labeled (e.g., fluorescently or enzymatically).
The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
This example describes the general method by which cells were separated using the cell separation reagents described below. Equal volumes of a cell separation reagent (see Table 1) and an acid citrate dextrose (ACD), CPDA (citrate, phosphate, dextrose, adenine) or heparinized umbilical cord blood sample were combined (25 ml each) in a sterile closed container (e.g., a 50 ml conical tube). Samples containing white blood cell counts greater than 20×106 cells/ml were combined one part blood with two parts cell separation reagent. Tubes were gently mixed on a rocker platform for 20 to 45 minutes at room temperature. Tubes were stood upright in a rack for 30 to 50 minutes to permit agglutinated cells to partition away from unagglutinated cells, which remained in solution. A pipette was used to recover unagglutinated cells from the supernatant without disturbing the agglutinate. Recovered cells were washed in 25 ml PBS and centrifuged at 500×g for 7 minutes. The cell pellet was resuspended in 4 ml PBS+2% human serum albumin.
Cells also were recovered from the agglutinate using a hypotonic lysing solution containing EDTA and ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA). Agglutinated cells were treated with 25 ml VitaLyse® (BioE, St. Paul, Minn.) and vortexed. After 10 minutes, cells were centrifuged at 500×g for 7 minutes and the supernatant was removed. Cells were resuspended in 4 ml PBS.
Recoveries of erythrocytes, leukocytes, lymphocytes, monocytes, granulocytes, T cells, B cells, NK cells, hematopoietic stem cells, and non-hematopoietic stem cells were determined by standard flow cytometry and immunophenotyping. Prior to flow cytometry, leukocyte recovery (i.e., white blood cell count) was determined using a Coulter Onyx Hematology Analyzer. Cell types were identified and enumerated by combining hematology analysis with flow cytometry analysis, identifying cells on the basis of light scattering properties and staining by labeled antibodies.
As shown in Table 2, 99.9% of erythrocytes were removed, 99.8% monocytes and granulocytes, 74% of B cells, 64.9% of NK cells, and 99.4% of the platelets were removed from the cord blood.
The cell separation reagent of Table 3 was used to isolate MLPC from the non-agglutinated supernatant phase. See
Briefly, 50-150 ml of CPDA anti-coagulated umbilical cord blood (<48 hours old) was gently mixed with an equal volume of cell separation composition described in Table 3 for 30 minutes. After mixing was complete, the container holding the blood/cell separation composition mixture was placed in an upright position and the contents allowed to settle by normal 1×g gravity for 30 minutes. After settling was complete, the non-agglutinated cells were collected from the supernatant. The cells were recovered from the supernatant by centrifugation then washed with PBS. Cells were resuspended in complete MSCGM™ (Mesenchymal stem cell growth medium, catalog #PT-3001, Cambrex, Walkersville, Md.) and adjusted to 2-9×106 cells/ml with complete MSCGM™. Cells were plated in a standard plastic tissue culture flask (e.g., Corning), chambered slide, or other culture device and allowed to incubate overnight at 37° C. in a 5% CO2 humidified atmosphere. All subsequent incubations were performed at 37° C. in a 5% CO2 humidified atmosphere unless otherwise noted. MLPC attached to the plastic during this initial incubation. Non-adherent cells (T-cells, NK-cells and CD34+ hematopoietic stem cells) were removed by vigorous washing of the flask or well with complete MSCGM™.
MLPC cultures were fed periodically by removal of the complete MSCGM™ and addition of fresh complete MSCGM™. Cells were maintained at concentrations of 1×105-1×106 cells/75 cm2 by this method. When cell cultures reached a concentration of 8×105-1×106 cells/75 cm2, cells were cryopreserved using 10% DMSO and 90% serum or expanded into new flasks. Cells were recovered from the adherent cultures by removal of the complete MSCGM™ and replacement with PBS+0.1% EGTA. Cells were incubated for 15-60 minutes at 37° C. then collected from the flask and washed in complete MSCGM™. Cells were then replated at 1×105 cells/mL. Cultures that were allowed to achieve confluency were found to have diminished capacity for both proliferation and differentiation. Subsequent to this finding, cultures were not allowed to achieve higher densities than 1×106 cells/75 cm2.
Cord blood derived MLPC isolated and cultured according to Examples 1 and 2 were cultured in standard MSCGM™ until confluency. Depending on the donor, MLPC cultures achieved confluency in 2-8 weeks. The morphology of these cells during growth and cultural maturation is shown in
In the early stage shown in
In summary, early during culture, cells appeared small and round, but had cytoplasmic projections, both finger-like and highly elongate projections, which help distinguish them from the other blood cells. Shortly after the initiation of the culture, the cells began to spread and flatten, taking on a morphology consistent with fibroblasts. Eventually, upon confluency, the cells grew in largely parallel orientation. Repeated growth of cultures to confluency resulted in their having diminished proliferation and differentiating capacity.
In order to determine the surface markers present on MLPC, freshly isolated cells were plated in 16 well chamber slides and grown to confluency. At various times during the culture (from 3 days post plating to post confluency), cells were harvested and stained for the following markers: CD45-FITC (BD/Pharmingen), CD34-PE (BD/Pharmingen), CD4-PE (BioE), CD8-PE (BioE), anti-HLA-DR-PE (BioE), CD41-PE (BioE), CD9-PE (Ancell), CD105-PE (Ancell), CD29-PE (Coulter), CD73-PE (BD/Pharmingen), CD90-PE (BD/Pharmingen), anti-hu Stem Cell Factor-FITC (R&D Systems), CD14-PE (BD/Pharmingen), CD15-FITC (Ancell), CD38-PE (BD/Pharmingen), CD2-PE (BD/Pharmingen), CD3-FITC (BD/Pharmingen), CD5-PE (BD/Pharmingen), CD7-PE (BD/Pharmingen), CD16-PE (BD/Pharmingen), CD20-FITC (BD/Pharmingen), CD22-FITC (BD/Pharmingen), CD19-PE (BD/Pharmingen), CD33-PE (BD/Pharmingen), CD10-FITC (BD/Pharmingen), CD61-FITC (BD/Pharmingen), CD133-PE (R&D Systems), anti-STRO-1 (R&D Systems) and Goat anti-mouse IgG(H+L)-PE (BioE), SSEA-3 (R&D Systems) and goat anti-rat IgG (H+L)-PE (BioE), SSEA-4 (R&D Systems) and goat anti-mouse IgG(H+L)-PE (BioE). The cell surface markers also were assessed in bone marrow MSC (Cambrex, Walkersville, Md.) and cord blood HSC (obtained from the non-adherent cells described above).
Briefly, cell culture medium was removed from the wells and the cells were washed 3× with Hank's Balanced Salt Solution+2% BSA. Cells were then stained with the antibodies for 20 minutes in the dark at room temperature. After incubation, the cells were washed 3× with Hank's Balanced Salt Solution+2% BSA and the cells were directly observed for fluorescence by fluorescent microscopy. Results obtained comparing cord blood derived MLPC with bone marrow-derived MSC's and cord blood derived hematopoietic stem cells (HSC) are outlined in Table 4.
After the second passage of MLPC cultures from Example 2, the cells were detached from the plastic surface of the culture vessel by substituting PBS containing 0.1% EGTA (pH 7.3) for the cell culture medium. The cells were diluted to a concentration of 1.3 cells/ml in complete MSCGM™ and distributed into a 96 well culture plate at a volume of 0.2 ml/well, resulting in an average distribution of approximately 1 cell/3 wells. After allowing the cells to attach to the plate by overnight incubation at 37° C., the plate was scored for actual distribution. Only the wells with 1 cell/well were followed for growth. As the cells multiplied and achieved concentrations of 1-5×105 cells/75 cm2, they were transferred to a larger culture vessel in order to maintain the cells at a concentration between 1×105 and 5×105 cells/75 cm2 to maintain logarithmic growth. Cells were cultured at 37° C. in a 5% CO2 atmosphere.
At least 52 clonal cell lines have been established using this procedure and were designated: UM081704-1-E2, UM081704-1-B6, UM081704-1-G11, UM081704-1-G9, UM081704-1-E9, UM081704-1-E11, UM081704-1-G8, UM081704-1-H3, UM081704-1-D6, UM081704-1-H11, UM081704-1-B4, UM081704-1-H4, UM081704-1-C2, UM081704-1-G1, UM081704-1-E10, UM081704-1-B7, UM081704-1-G4, UM081704-1-F12, UM081704-1-H1, UM081704-1-D3, UM081704-1-A2, UM081704-1-B11, UM081704-1-D5, UM081704-1-E4, UM081704-1-C10, UM081704-1-A5, UM081704-1-E8, UM081704-1-C12, UM081704-1-E5, UM081704-1-A12, UM081704-1-C5, UM081704-1-A4, UM081704-1-A3, MH091404-2#1-1.G10, UM093004-1-A3, UM093004-1-B7, UM093004-1-F2, UM093004-1-A12, UM093004-1-G11, UM093004-1-G4, UM093004-1-B12, UM093004-2-A6, UM093004-2-A9, UM093004-2-B9, UM093004-2-C5, UM093004-2-D12, UM093004-2-H3, UM093004-2-H11, UM093004-2-H4, UM093004-2-A5, UM093004-2-C3, and UM093004-2-C10. The surface markers of clonal cell line UM081704-1-E8 were assessed according to the procedure outlined in Example 4 and found to be the same as the “mature MLPC” having fibroblast morphology, as shown in Table 4.
A population of MLPC and clonal cell line UM081704-1-E8 each were cultured in complete MSCGM™ and grown under logarithmic growth conditions outlined above. Cells were harvested by treatment with PBS+0.1% EGTA and replated at 5×103 to 2×104/ml in complete MSCGM™. The cells were allowed to adhere overnight and then the medium was replaced with Osteogenic Differentiation Medium (catalog #PT-3002, Cambrex,) consisting of complete MSCGM™ supplemented with dexamethasone, L-glutamine, ascorbate, and β-glycerophosphate. Cells were cultured at 37° C. in a 5% CO2 atmosphere and fed every 3-4 days for 2-3 weeks. Deposition of calcium crystals was demonstrated by using a modification of the Alizarin red procedure and observing red staining of calcium mineralization by phase contrast and fluorescent microscopy.
A population of MLPC and clonal cell line UM081704-1-E8 each were plated in complete MSCGM™ at a concentration of 1×104 to 2×105 cells/mL medium and cultured at 37° C. in a 5% CO2 atmosphere. Cells were allowed to re-adhere to the culture plate and were fed every 3-4 days until the cultures reached confluency. At 100% confluency, cells were differentiated by culture in Adipogenesis differentiation medium (catalog #PT-3004, Cambrex) consisting of complete MSCGM™ supplemented with hu-insulin, L-glutamine, dexamethasone, indomethacin, and 3-isobutyl-1-methyl-xanthine, for at least 14 days.
To assess differentiation, the cells were stained with Oil Red stain specific for lipid. Confluent cultures of MLPC display a fibroblast-like morphology and do not display any evidence of liposome development as assessed by Oil Red staining. In contrast, MLPC differentiated with Adipogenic medium for 3 weeks exhibit liposomes that are characteristic of adipocytes (i.e., bright white vessels in cytoplasm) and that stain red with the Oil Red stain. MLPC differentiated with Adipogenic medium also fluoresce green with Nile Red stain specific for trigycerides. Undifferentiated cells retain their fibroblast-like morphology and do not stain.
MLPC (both a population and clonal cell line UM081704-1-E8) were plated in complete MSCGM™ at a concentration of 1.9×104 cells/well within a 4-chamber fibronectin pre-coated slide and allowed to attach to the plate for 24-48 hr at 37° C. in a 5% CO2 atmosphere. Medium was removed and replaced with 10 μM 5-azacytidine (catalog #A 1287, Sigma Chemical Co.) and incubated for 24 hours. Cells were washed twice with PBS and fed with SkGM™ Skeletal Muscle Cell Medium (catalog #CC-3160, Cambrex) containing recombinant human epidermal growth factor (huEGF), human insulin, Fetuin, dexamethasone, and recombinant human basic fibroblast growth factor (100 ng/mL) (huFGF-basic, catalog #F0291, Sigma Chemical Co., St. Louis, Mo.). Cells were fed every 2-3 days for approximately 21 days. Control wells were fed with MSCGM™ while experimental wells were fed with SkGM™ (as described above).
Cultures were harvested 7 days post initiation of myocytic culture. Culture supernatant was removed and cells were fixed for 2 hours with 2% buffered formalin. Cells were permeabilized with PermaCyte™ (BioE, St. Paul, Minn.) and stained with mouse monoclonal antibody specific for human fast skeletal myosin (MY-32, catalog #ab7784, Abcam, Cambridge, Mass.) or mouse monoclonal antibody specific for alpha actinin (BM 75.2, catalog #ab11008, Abcam). Cells were incubated with the primary antibody for 20 minutes, washed with PBS and counter stained with goat anti-mouse IgG (H+L)-PE (BioE, St. Paul, Minn.). The myocytic culture contained fast skeletal muscle myosin and alpha actinin, which is indicative of the transdifferentiation of MLPC to skeletal muscle cells.
Bone marrow derived hMSC (Cambrex), cord blood MLPC, and MLPC clonal cell line were grown under logarithmic growth conditions described above. Cells were harvested as described above and replated at 0.8×104 cells per chamber in 4-chamber slides that were pre-coated with poly-D-lysine and laminin (BD Biosciences Discovery Labware, catalog #354688) in 0.5 mL of NPMM™ (catalog #CC-3209, Cambrex) containing huFGF-basic, huEGF, brain-derived neurotrophic factor, neural survival factor-1, fibroblast growth factor-4 (20 ng/mL), and 200 mM GlutaMax I Supplement (catalog #35050-061, Invitrogen, Carlsbad, Calif.). The medium was changed every 2-3 days for 21 days. Neurospheres developed after 4 to 20 days. Transformation of MLPC to neural lineage was confirmed by positive staining for nestin (monoclonal anti-human nestin antibody, MAB1259, clone 196908, R&D Systems), class III beta-tubulin (tubulin b-4) (monoclonal anti-neuron-specific class III beta-tubulin antibody, MAB1195, Clone TuJ-1, R&D Systems), glial fibrillary acidic protein (GFAP) (monoclonal anti-human GFAP, HG2b-GF5, clone GF5, Advanced Immunochemical, Inc.), and galactocerebroside (GalC) (mouse anti-human GalC monoclonal antibody MAB342, clone mGalC, Chemicon).
Cells were further differentiated into neurons by the addition of 10 ng/mL BDNF (catalog #B3795, Sigma Chemical Co.) and 10 ng/mL NT3 (catalog #N1905, Sigma Chemical Co.) to the neural progenitor maintenance medium and further culturing for 10-14 days. Neurospheres were further differentiated into astrocytes by the addition of 10−6 M retinoic acid (catalog #R2625, Sigma Chemical Co.), 10 ng/mL LIF (catalog #L5158, Sigma Chemical Co.) and 10 ng/mL CNTF (catalog #C3710, Sigma Chemical Co.) to the neural progenitor maintenance medium and further culturing for 10-14 days. Neurospheres were further differentiated into oligodendrocytes by the addition of 10−6 M T3 (catalog #T5516, Sigma Chemical Co.) to the neural progenitor maintenance medium and further culturing for 10-14 days. Differentiation to oligodendrocytes was confirmed by positive staining for myelin basic protein (MBP) (monoclonal anti-MBP, catalog #ab8764, clone B505, Abcam).
MLPC were plated at 1.9×104 cells per well within a 4-chamber slide (2 cm2). Cells were fed with 1 ml of endothelial growth medium-microvasculature (FGM™-MV, catalog #CC-3125, Cambrex) containing heparin, bovine brain extract, human recombinant epithelial growth factor and hydrocortisone. The cells were fed by changing the medium every 2-3 days for approximately 21 days. Morphological changes occurred within 7-10 days. Differentiation of MLPC's to endothelial lineage was assessed by staining for CD62E [E-selectin, mouse anti-human CD62E monoclonal antibody, catalog #551145, clone 68-5H11, BD Pharmingen] and CD102 [ICAM-2, monoclonal anti-human ICAM-2, MAB244, clone 86911, R&D Systems], CD34 [BD Pharmingen] and STRO-1 (R&D Systems]. Control MLPC cultures grown in MSCGM for 14 days were negative for CD62E staining and CD 102, CD34 and STRO-1, while differentiated cultures were positive for both CD62E, CD102, CD34, and STRO-1.
MLPC were plated at a concentration of 1×105 cells/cm2 in vitro in HCM™ medium (catalog #CC-3198, Cambrex) containing ascorbic acid, hydrocortisone, transferrin, insulin, huEGF, recombinant human hepatocyte growth factor (40 ng/mL), huFGF-basic (20 ng/mL), recombinant human fibroblast growth factor-4 (20 ng/mL), and stem cell factor (40 ng/mL). Cells were cultured for 29 or more days to induce differentiation to precursor cells of both hepatocytes and pancreatic cells lineage. MLPC changed from a fibroblast morphology to a hepatocyte morphology, expressed cell surface receptors for Hepatocyte Growth Factor, and produced both human serum albumin, a cellular product of hepatocytes, and insulin, a cellular product of pancreatic islet cells, both confirmed by intracellular antibody staining on day 30.
MLPCs were isolated from 4 of 16 umbilical cord blood units (American Red Cross) and expanded as described in Example 2. In particular, following homo- and heterophilic aggregation of undesired cell populations and subsequent sedimentation by gravity, the supernatant containing stem cells was expressed. After overnight incubation (5% CO2/37° C.) in a T-flask in MSCGM™, non-adherent cells were washed, leaving adherent cells to expand in culture. As MLPC colonies were observed, cells were further enriched by detachment (PBS/0.1% EGTA), generally at 60-70% confluence, and transfer to a new T-flask. Cloning was achieved by a standard limited-dilution technique as discussed in Example 5. Clonal cell lines UM081704-1 C3 and E8 were used.
For differentiation assays, cultures were grown to approximately 80% confluence in MSCGM™ before adding Small Airway Epithelial Growth Media (SAGM™; Cambrex, Inc. CC-3118), a maintenance media designed for cultivation of terminally differentiated airway epithelium. SAGM™ consists of basal medium plus the following factors: bovine pituitary extract, hydrocortisone, human epidermal growth factor, epinephrine, insulin, triiodothyronine, transferrin, gentamicin/amphotericin-B, retinoic acid and BSA-fatty acid free. SAGM™ was changed on days 3-4; cells were harvested (PBS/0.1% EGTA) on day 8, and analyzed by transmission electron microscopy (TEM) and reverse transcriptase (RT)-PCR. For immunofluorescence (IF) staining, MLPC were initially plated at 2×104/well in a non-coated four-well chamber slide (Lab-Tek II; Nalge Nunc International, Rochester, N.Y., USA) then cultured as described above. Clonal cell lines were differentiated as above; however, they were harvested on day 3 for analysis by TEM and RT-PCR.
Cells were visualized by light microscopy (Eclipse TS100; Nikon Inc., Melville, N.Y., USA) throughout culture. Upon harvest, a cell pellet was made and prepared for analysis by TEM. Briefly, the pellet was rinsed in PBS and fixed in 2.5% glutaraldehyde in 0.1 m PBS buffer for 30 min. The sample was then post-fixed in 1% osmium tetroxide in 0.1 m PBS (30 min) and rinsed in PBS (three washes, 10 min each). The cells were enrobed and pelleted in 2% molten agarose, chilled at 4° C. for 30 min, diced into 1-mm cubes for dehydration through graded ethanol, and embedded in EMbed812 epoxy resin (EMS, Hatfield, Pa., USA). Ultra-thin sections of silver-gold interference color were stained in 3% aqueous uranyl acetate (20 min) then in Sato triple lead stain (3 min) prior to examination using an FEI CM12 Electron Microscope (FEI Co., Hillsboro, Oreg., USA).
Total RNA was isolated from MLPC in culture by employing the method of Chomezynski (BioTechniques 15:532-7 (1993)). Briefly, TRI Reagent (Molecular Research Center, Cincinnati, Ohio, USA) was added directly to the cells in culture flasks, causing simultaneous cell lysis and RNA solubilization. Reverse transcription was accomplished in a reaction containing 2.5 μg RNA, 1.0 μL random hexamers (5 μm final), 1 μL reverse transcriptase (Superscript™ Life Technologies, Rockville, Md.), 8 μL dNTP (2.5 mm each), 4 μL MgCl2 (1.5 mm) and 2 μL 10×/buffer in a final volume of 20 μL, with incubation at 42° C. for 45 min followed by 15 min at 70° C.
A two-step nested RT-PCR strategy was used to amplify the surfactant protein C cDNA. Table 5 contains the primer sequences and expected RT-PCR product sizes for surfactant protein C (SPC). One microliter from the cDNA pool was used in the first PCR amplification with the following conditions: 5 min hot start at 95° C., 30 cycles of 95° C. for 30 s, 57° C. for 30 s, 72° C. for 30 s and a final extension for 5 min at 72° C. Two microliters of each primer diluted to 20 pmol/mL were used in each reaction. One microliter of the product from the first reaction was used as a template for the nested reaction, with the same cycling conditions and primer concentrations outlined above. RT-PCR amplification of beta-globin, a housekeeping gene, was used to monitor the quality of the mRNA and control for the efficiency of the RT step. PCR products were electrophoresed on 2% agarose gels and visualized by ethidium bromide staining. Product sizes were compared to a 100-bp ladder (Invitrogen, Carlsbad, Calif., USA).
Differentiated cells also were stained for proSPC using an immunostaining procedure similar to Ali et al. (Tissue Eng. 2002; 8:541-50) with minor modifications. Cells were washed with HBSS+1% BSA twice, treated with 4% paraformaldehyde and incubated at room temperature for 20 min. The cells then were washed twice with HBSS+1% BSA. The primary pro-SPC Ab (Chemicon, AB3428, Temecula, Calif., USA) was added to the cells at a 1:125 dilution and incubated overnight at 4° C. After the primary Ab incubation, slides were washed twice with HBSS+1% BSA. The secondary Alexa Fluor 594 goat anti-rabbit Ab (Invitrogen, A11072) then was added at a 1:50 dilution and incubated with the cells for 20 min. Final HBSS+1% BSA washes were performed, and cover slips were placed onto the glass slides. Cells were viewed under a fluorescence microscope (Eclipse E200; Nikon Inc., Melville, N.Y., USA).
By day 8 of culture (day 3 for clonal line UM081704-1 C3 and E8), cells in SAGM™ possessed a more epithelioid morphology; controls held in MSCGM™ maintained a fibroblast-like morphology (compare
SPC mRNA was evident in RNA samples from mixed (n=4) and clonal (n=2) MLPC differentiated in SAGM™. However, SPC mRNA was not identified in RNA samples from MLPC controls. The presence of pro-SPC protein was confirmed by IF staining of both mixed (n=3) and clonal (n=2) stem cell lines. Essentially all the MLPC of each culture induced in SAGM™ were successfully differentiated. MLPC controls (maintained in MSCGM™) were negative. Table 6 summarizes all the results.
Total RNA was isolated from cultured MLPC (3 control lines maintained in MSCGM™ and 3 induced/differentiated cell lines maintained in SAGM™ for either 3 days for clonal cell lines or 8 days for mixed cell lines). The TRI REAGENT (Molecular Research Center, Inc.) protocol was used to isolate the total RNA, which then was cleaned using the RNeasy mini kit protocol (Qiagen Inc.). Total RNA was used to synthesize double stranded cDNA according to the manufacturer's instructions (Affymetrix, Inc.). The first strand synthesis reaction was performed using 1 μg RNA, SuperScript II Reverse Transcriptase (Invitrogen), and T7-(dT)24 primer (Genset Corp.). Second strand synthesis reaction followed using E. coli DNA ligase, E. coli DNA polymerase I, and E. coli RNase H (Invitrogen). The double stranded cDNA was column-purified using the Affymetrix supplied module (Affymetrix, Inc.) and used as template in an in vitro T7 transcription reaction using the MEGAscript T7 high yield transcription kit (Ambion) and biotinylated nucleotides Biotin-11-CTP, Biotin-16-UTP (NEN, Perkin-Elmer, Boston, Mass.). A 20 μg cRNA aliquot was fragmented in 1× fragmentation buffer (40 mM Tris-acetate pH 8.1, 100 mM KOAc, 30 mM MgOAc) at 94° C. for 35 min. Assessment of fragmented, labeled cRNA was performed via use of an Agilent chip (Agilent Technologies, Inc). Fifteen μg of the fragmented cRNA was hybridized to a human GeneChip probe array (Affymetrix, U133 plus 2.0) for 16 hours at 45° C. The probe arrays were washed, stained, and scanned in an Affymetrix fluidics station and scanner following the manufacturer's protocols. CEL files were incorporated in Expressionist software Refiner (Genedata AG) and condensed using the Mas5 algorithm.
Over 23,000 data points were generated for each of the 6 samples (3 distinct biological replicates of control and induced samples). The data were grouped into control (maintained in MSCGM™) and induced (differentiated with SAGM™) for comparison of differential gene expression. Comparison of the two mixed MLPC (each with 1 control and 1 induced sample) was performed using Expressionist (Genedata AG) software and the Student's T-test. With a P value of 0.01 and an inter-group gap of 2.0, 373 genes were found to be differentially expressed between the control and induced groups. See Table 7. Two hundred and fifteen (215) genes were up-regulated in the induced MLPC relative to the control MLPC while 158 genes were down-regulated in the induced MLPC relative to the control MLPC. Functional categories of genes included those for: cell cycle control (P21, cyclin L1, cyclin M2 and cyclin M3); signaling (N-Myc and STAT interactor); protein protection (gp96-expressed in non-small cell lung cancers); and lamellar body formation and maintenance (V-ATPases). Additional genes that were noted to be differentially regulated, but were not included in the above list due to increased standard deviations, include: α-1 antitrypsin, a serine (or cysteine) protease inhibitor (expressed in lung epithelium) and LAMP-1 (required for the functioning of lysosomes and lamellar bodies).
Comparison of the two mixed MLPC lines and one clonal line (C3) (each with 1 control and 1 induced sample) also was performed using Expressionist (Genedata AG) software and the Student's T-test. With a P value of 0.01 and an inter-group gap of 1.0, 611 genes were found to be differentially expressed between the control and induced groups. See
While the invention has been described in conjunction with the foregoing detailed description and examples, the foregoing description and examples are intended to illustrate and not to limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the claims.
This application claims benefit of U.S. Application No. 60/792,511, filed Apr. 17, 2006, which is incorporated by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5004681 | Boyse et al. | Apr 1991 | A |
| 5130144 | Civin | Jul 1992 | A |
| 5192553 | Boyse et al. | Mar 1993 | A |
| 5453357 | Hogan | Sep 1995 | A |
| 5486359 | Caplan et al. | Jan 1996 | A |
| 5580714 | Polovina | Dec 1996 | A |
| 5744347 | Wagner et al. | Apr 1998 | A |
| 5750397 | Tsukamoto et al. | May 1998 | A |
| 5789147 | Rubinstein et al. | Aug 1998 | A |
| 5827735 | Young et al. | Oct 1998 | A |
| 5827740 | Pittenger | Oct 1998 | A |
| 5830651 | Cauley et al. | Nov 1998 | A |
| 5843780 | Thomson | Dec 1998 | A |
| 5877299 | Thomas et al. | Mar 1999 | A |
| 5908782 | Marshak et al. | Jun 1999 | A |
| 5928214 | Rubinstein et al. | Jul 1999 | A |
| 5942225 | Bruder et al. | Aug 1999 | A |
| 5965436 | Thiede et al. | Oct 1999 | A |
| 5968829 | Carpenter | Oct 1999 | A |
| 6030836 | Thiede et al. | Feb 2000 | A |
| 6103530 | Carpenter | Aug 2000 | A |
| 6140121 | Ellington et al. | Oct 2000 | A |
| 6200806 | Thomson | Mar 2001 | B1 |
| 6251669 | Luskin | Jun 2001 | B1 |
| 6280718 | Kaufman et al. | Aug 2001 | B1 |
| 6306575 | Thomas et al. | Oct 2001 | B1 |
| 6322784 | Pittenger et al. | Nov 2001 | B1 |
| 6328960 | McIntosh et al. | Dec 2001 | B1 |
| 6387367 | Davis-Sproul et al. | May 2002 | B1 |
| 6432711 | Dinsmore et al. | Aug 2002 | B1 |
| 6436704 | Roberts et al. | Aug 2002 | B1 |
| 6491918 | Thomas et al. | Sep 2002 | B1 |
| 6461645 | Boyse et al. | Oct 2002 | B1 |
| 6465247 | Weissman et al. | Oct 2002 | B1 |
| 6482926 | Thomas et al. | Nov 2002 | B1 |
| 6491917 | Thomas et al. | Dec 2002 | B1 |
| 6498034 | Strobl | Dec 2002 | B1 |
| 6569427 | Boyse et al. | May 2003 | B1 |
| 6605275 | Boyse et al. | Aug 2003 | B1 |
| 6645727 | Thomas et al. | Nov 2003 | B2 |
| 6680198 | Snyder et al. | Jan 2004 | B1 |
| 6709864 | Pittenger et al. | Mar 2004 | B1 |
| 6740493 | Long et al. | May 2004 | B1 |
| 6750326 | Thomas et al. | Jun 2004 | B2 |
| 6761883 | Weissman et al. | Jul 2004 | B2 |
| 6767737 | Wilson et al. | Jul 2004 | B1 |
| 6777231 | Katz et al. | Aug 2004 | B1 |
| 6777233 | Carpenter | Aug 2004 | B2 |
| 6800480 | Bodnar et al. | Oct 2004 | B1 |
| 6835377 | Goldberg et al. | Dec 2004 | B2 |
| 6852533 | Rafii et al. | Feb 2005 | B1 |
| 6875430 | McIntosh et al. | Apr 2005 | B2 |
| 6887704 | Peled et al. | May 2005 | B2 |
| 6911201 | Merchav et al. | Jun 2005 | B1 |
| 6946293 | Lu et al. | Sep 2005 | B1 |
| 6962698 | Peled et al. | Nov 2005 | B1 |
| 6986887 | Lawman et al. | Jan 2006 | B2 |
| 6991897 | Smith et al. | Jan 2006 | B2 |
| 7015037 | Furcht et al. | Mar 2006 | B1 |
| 7045148 | Hariri | May 2006 | B2 |
| 7122178 | Simmons et al. | Oct 2006 | B1 |
| 7160723 | Collins et al. | Jan 2007 | B2 |
| 7255879 | Hariri | Aug 2007 | B2 |
| 20010034061 | Csete et al. | Oct 2001 | A1 |
| 20010046489 | Habener et al. | Nov 2001 | A1 |
| 20020012903 | Goldman et al. | Jan 2002 | A1 |
| 20020028510 | Sanberg et al. | Mar 2002 | A1 |
| 20020045196 | Mahoney et al. | Apr 2002 | A1 |
| 20020064519 | Bruder et al. | May 2002 | A1 |
| 20020068045 | Reubinoff et al. | Jun 2002 | A1 |
| 20020132987 | Anderson | Sep 2002 | A1 |
| 20020164308 | Reubinoff et al. | Nov 2002 | A1 |
| 20020164790 | Warburton et al. | Nov 2002 | A1 |
| 20020164794 | Wernet | Nov 2002 | A1 |
| 20020168763 | Yan et al. | Nov 2002 | A1 |
| 20020177227 | Kraus et al. | Nov 2002 | A1 |
| 20020192816 | Roberts et al. | Dec 2002 | A1 |
| 20030003084 | Seshi | Jan 2003 | A1 |
| 20030027233 | Collins et al. | Feb 2003 | A1 |
| 20030032179 | Hariri | Feb 2003 | A1 |
| 20030092078 | Thomas et al. | May 2003 | A1 |
| 20030113910 | Levanduski | Jun 2003 | A1 |
| 20030134416 | Yamanishi et al. | Jul 2003 | A1 |
| 20030157078 | Hall et al. | Aug 2003 | A1 |
| 20030161818 | Weiss et al. | Aug 2003 | A1 |
| 20030165852 | Schueler et al. | Sep 2003 | A1 |
| 20030180269 | Hariri | Sep 2003 | A1 |
| 20030203483 | Seshi | Oct 2003 | A1 |
| 20030235563 | Strom et al. | Dec 2003 | A1 |
| 20030235909 | Hariri et al. | Dec 2003 | A1 |
| 20040018621 | Reid et al. | Jan 2004 | A1 |
| 20040028660 | Hariri et al. | Feb 2004 | A1 |
| 20040058398 | Sarvetnick et al. | Mar 2004 | A1 |
| 20040058412 | Ho et al. | Mar 2004 | A1 |
| 20040107453 | Furcht et al. | Jun 2004 | A1 |
| 20040121464 | Rathjen et al. | Jun 2004 | A1 |
| 20040137612 | Baksh et al. | Jul 2004 | A1 |
| 20040142463 | Walker et al. | Jul 2004 | A1 |
| 20040161419 | Strom et al. | Aug 2004 | A1 |
| 20040171147 | Hariri | Sep 2004 | A1 |
| 20040203142 | Rai | Oct 2004 | A1 |
| 20040219136 | Hariri | Nov 2004 | A1 |
| 20040228847 | Goldschmidt-Clermont et al. | Nov 2004 | A1 |
| 20040259254 | Honmou et al. | Dec 2004 | A1 |
| 20050019865 | Kihm et al. | Jan 2005 | A1 |
| 20050019908 | Hariri | Jan 2005 | A1 |
| 20050019911 | Gronthos et al. | Jan 2005 | A1 |
| 20050032209 | Messina et al. | Feb 2005 | A1 |
| 20050037493 | Mandalam et al. | Feb 2005 | A1 |
| 20050048035 | Fraser et al. | Mar 2005 | A1 |
| 20050053588 | Yin | Mar 2005 | A1 |
| 20050054098 | Mistry et al. | Mar 2005 | A1 |
| 20050058629 | Harmon et al. | Mar 2005 | A1 |
| 20050058630 | Harris et al. | Mar 2005 | A1 |
| 20050058631 | Kihm et al. | Mar 2005 | A1 |
| 20050059147 | Seshi | Mar 2005 | A1 |
| 20050063961 | Friedlander et al. | Mar 2005 | A1 |
| 20050074435 | Casper et al. | Apr 2005 | A1 |
| 20050095703 | Semb et al. | May 2005 | A1 |
| 20050106554 | Palecek et al. | May 2005 | A1 |
| 20050118715 | Hariri et al. | Jun 2005 | A1 |
| 20050124003 | Atala et al. | Jun 2005 | A1 |
| 20050142118 | Wernet | Jun 2005 | A1 |
| 20050158289 | Simmons et al. | Jul 2005 | A1 |
| 20050176139 | Chen et al. | Aug 2005 | A1 |
| 20050181502 | Furcht et al. | Aug 2005 | A1 |
| 20050255592 | Collins et al. | Nov 2005 | A1 |
| 20050260748 | Chang et al. | Nov 2005 | A1 |
| 20050260751 | Lucas et al. | Nov 2005 | A1 |
| 20060008450 | Verfaillie et al. | Jan 2006 | A1 |
| 20060030039 | Chen et al. | Feb 2006 | A1 |
| 20060037092 | Lawman et al. | Feb 2006 | A1 |
| 20060040392 | Collins et al. | Feb 2006 | A1 |
| 20060078993 | Phan et al. | Apr 2006 | A1 |
| 20060134636 | Stanton | Jun 2006 | A1 |
| 20060141493 | West et al. | Jun 2006 | A1 |
| 20060154366 | Brown et al. | Jul 2006 | A1 |
| 20060206953 | Lanza et al. | Sep 2006 | A1 |
| 20070292398 | Collins | Dec 2007 | A1 |
| Number | Date | Country |
|---|---|---|
| 03 01 7676.2 | Aug 2004 | EP |
| WO 9011354 | Oct 1990 | WO |
| WO 9101140 | Feb 1991 | WO |
| WO 9304169 | Mar 1993 | WO |
| WO 0236751 | May 2002 | WO |
| WO 03055989 | Jul 2003 | WO |
| WO 03068937 | Aug 2003 | WO |
| WO 03078610 | Sep 2003 | WO |
| WO 2004024875 | Mar 2004 | WO |
| WO 2004029208 | Apr 2004 | WO |
| WO 2005017132 | Feb 2005 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20070249047 A1 | Oct 2007 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60792511 | Apr 2006 | US |
